Contractual research, development and production organization (CRDMO) Anthem Biosciences that triggers its £Next week, 3,395 crore initial public offers (IPO) banks geopolitical tail winds because global pharmaceutical companies give up from China to unlock value and growth, the company management said on Wednesday.
“The good news is that … China is a monster. So we have so many growths,” said Ajay Bhardwaj, CEO and CEO. “At this point, I think we are at a very good infection point,” Bhardwaj said, adding that the company has seen an increase in requests for proposals (RFP) from global pharmaceutical companies.
In addition, the company has 16 late phase projects that will soon be commercialized. “We have a significant opportunity to pay this growth,” Bhardwaj said.
Also read | Torrent Pharma bet on JB chemicals, but can the acquisition add?
Anthem helps global pharmaceutical companies with everything from early research of drugs to final development and launch of new medicines.
Anthem Biosciences opens his £3,395 CRORE IPO for public subscriptions from July 14th to July 16, with anchor will be held on July 11th. The offer is a completely offer for sale (offs) without not being released new shares. The whole return will go to existing promoters and shareholders selling their share.
Promotor shares in society are 76.88% before the island. The company will reduce this to 74.6%to comply with the regulations for securities and exchange councils (SEBI), she said.
The price belt was set at £540 to £570 per share, with nominal value £2.
At the upper end of the band would end up the company’s award £31 800 crore.
Competition with China
The CRDMO Indian sector is ready to see revenue growth by 13-15% in this fiscal year, as supply chains around the world diversify from China in the middle of geopolitical uncertainty, according to the report on Crisel 2025.
“Competition for all in India is Chinese society … They take most of the business,” Bhardwaj said.
Also read | Pharmaceutical companies are likely to publish sales growth 11%, EBITDA in Q1FY26: Report
Currently, India represents less than 5% of the global CRDM market dominated by the US, Europe and China, according to Crisil Ratings research.
China has a scale, Bhardwaj said. “You have to compete with innovations. So, that’s what we’ve made a difference,” he added.
Anthem works with new chemical entities and biologists and has the ability to work on the conjugates of RNAI, antibodies, peptides, lipides and oligonucleotides. It also produces special ingredients such as probiotics and nutritional activation for India and the rest of the world markets.
The company also focuses on increasing its production capacity by expanding capacity in one of its two existing units and the establishment of two new units.
Also read | Apollo Hospitals shares a 4% jump to a list of digital health, ARMS pharmacy
In FY25, Anthem’s revenue increased by 30% year -on -year £1,844 crore while the profit after tax increased to £451 crore, 23% compared to the previous year. The company had 36.81%in FY25.
In India, the peers of Anthem List Syngene International, Sai Life Sciences, Cohance and Divi’s Laboratories include.
(Tagstotranslate) China
